 Paclitaxel, gemcitabine and cisplatin have all been approved by the United States Food and Drug Administration FDA. Gemcitabine and cisplatin is a standard treatment for bladder cancer. There have been studies that show that paclitaxel and cisplatin have antitumor activity in bladder cancer. European researchers studied paclitaxel, gemcitabine and cisplatin same drug combination in this trial and found that the combination provided good disease control and was well tolerated. Investigators are studying the same drug combination, but at different dosages and schedule. 